Description

Summary of the evidence landscape for over-the-counter cannabidiol (CBD) products, highlighting the gap between public interest and clinical evidence. The review examines the rapid growth of consumer CBD products over the preceding five years.

Figure 1

Diagram

Source Paper

Lack of evidence for the effectiveness or safety of over-the-counter cannabidiol products.

Therapeutic advances in psychopharmacology (2020)

PMID: 32973998

DOI: 10.1177/2045125320954992

Cite This Figure

![Figure 1: Summary of the evidence landscape for over-the-counter cannabidiol (CBD) products, highlighting the gap between public interest and clinical evidence. The review examines the rapid growth of consumer CBD products over the preceding five years.]()

> Source: Edward Chesney et al. "Lack of evidence for the effectiveness or safety of over-the-counter cannabidiol." *Therapeutic advances in psychopharmacology*, 2020. PMID: [32973998](https://pubmed.ncbi.nlm.nih.gov/32973998/)

<figure>
  <img src="" alt="Summary of the evidence landscape for over-the-counter cannabidiol (CBD) products, highlighting the gap between public interest and clinical evidence. The review examines the rapid growth of consumer CBD products over the preceding five years." />
  <figcaption>Figure 1. Summary of the evidence landscape for over-the-counter cannabidiol (CBD) products, highlighting the gap between public interest and clinical evidence. The review examines the rapid growth of consumer CBD products over the preceding five years.<br>  Source: Edward Chesney et al. "Lack of evidence for the effectiveness or safety of over-the-counter cannabidiol." <em>Therapeutic advances in psychopharmacology</em>, 2020. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/32973998/">32973998</a></figcaption>
</figure>

Related Evidence

Zinc for Sleep Onset Difficulty

Grade A · 32 studies